The goal was to identify alpha-1-adrenergic receptor (AR) subtypes in human coronary arteries.
predominant ␣1-AR subtype in the human myocardium, on the basis of messenger ribonucleic acid (mRNA) assay (10) . Taken together, these previous results suggest that ␣1-AR subtype expression is different in the human heart than the mouse heart.
The distribution of cardiac ␣1-AR subtypes has significant physiological impact in the mouse, where the myocardial ␣1A and ␣1B mediate adaptive and beneficial effects, including positive inotropy, physiological hypertrophy, and protection from myocyte death (6, (11) (12) (13) . The coronary ␣1D mediates vasoconstriction (7, 8) . In humans, nonselective blockade of all ␣1-subtypes can be associated with heart failure (14, 15) . These results and others raise the possibility that the human heart ␣1A and ␣1B subtypes should not be blocked and might even be targets for selective agonists to treat myocardial disease (12, 16) . Thus, it could be significant clinically if human coronary arteries express predominantly the ␣1D subtype, as in the mouse (7, 8) , rather than the ␣1A subtype, as reported previously (9) .
In this study, we re-examined the ␣1-AR subtypes in human epicardial coronary arteries, and measured ␤-ARs for comparison. Our results show that the ␣1D is the predominant and functional coronary ␣1-AR subtype, whereas the ␣1A and ␣1B are expressed at very low levels. We contrast this finding with the minimal expression of the ␣1D in human ventricular myocardium. We also find that ␣1-AR levels in coronary arteries are approximately onethird the level of ␤-ARs, most of which are the ␤2 subtype.
Methods

Patients.
With the approval of the University of California, San Francisco (UCSF) Committee for Human Research and with full informed consent, we obtained heart tissue from transplant recipients or unused donors provided by the California Transplant Donors Network (CTDN). Tissue collection. The heart was explanted after cold cardioplegia, under anesthesia and analgesia with fentanyl, midazolam, rocuronium, and isoflurane at UCSF, and with varied agents at the CTDN hospitals. The explanted heart was placed immediately in ice-cold physiologic solution, epicardial coronary arteries were dissected, cleaned rapidly of fat, flash frozen in liquid nitrogen, and stored at Ϫ80°C.
Ribonucleic acid (RNA) preparation. Coronaries were pulverized in a liquid nitrogen-cooled mortar and homogenized (Polytron) in TRIzol reagent (Invitrogen, Gibco BRL, Gaithersburg, Maryland). Myocardium was homogenized directly in TRIzol. The RNA was extracted with chloroform and isopropanol, purified on Qiagen Mini-Prep columns, and treated with DNase (Turbo DNAfree, Ambion, Austin, Texas). We found no significant RNA degradation (Agilent 2100 BioAnalyzer, Palo Alto, California). Quantitative real-time reverse transcription (RT) polymerase chain reaction. The RT reactions used 1 g RNA, SuperScript III Reverse Transcriptase (Invitrogen), random hexamers (Invitrogen), and oligo-dT (Roche, Nutley, New Jersey). Quantitative real-time RT polymerase chain reaction (qRT-PCR) was done in triplicate in an ABI PRISM 7900HT Sequence Detection System with 5% of the RT product, primers at 125 nmol/l, and SYBR Green Master (Roche) with ROX reference dye. Data were analyzed with SDS software version 2.3 (Applied Biosystems, Foster City, California).
Relative quantitation of PCR products used the ⌬⌬CT method, where arbitrary units were 2
Ϫ⌬⌬CT ϫ 1,000, CT ϭ cycles to threshold, and ⌬⌬CT ϭ (mean target gene CT) Ϫ (mean CT of 2 reference genes, ␤-actin, and TATAbinding protein, for improved accuracy). Radioligand binding. Multiple protocols for membrane preparation from single arteries did not yield sufficient protein for reliable binding. Therefore, 15 epicardial coronaries totaling 10.2 g wet weight were pooled from 11 patients, pulverized in a liquid nitrogen-cooled mortar, homogenized in lysis buffer (5 mmol/l Tris-hydrochloride, 5 mmol/l ethylenediaminetetraacetic acid, 250 mmol/l sucrose pH 7.4 plus phenylmethylsulfonyl fluoride), and centrifuged at 1,000 g for 15 min. The supernatant was saved, and the pellet containing insoluble material was washed in lysis buffer and recentrifuged. The combined supernatants were centrifuged at 100,000 g for 1 h, and the resulting pellet was homogenized in lysis buffer and centrifuged at 100,000 g for 1 h. The resulting final membrane pellet, containing both plasma and intracellular membranes, was resuspended (50 mmol/l Tris pH 7.4, 1 mmol/l ethylenediaminetetraacetic acid) and used for ␣1-and ␤-AR binding.
The ␣1-AR saturation binding used 200 g membrane protein in 1 ml/tube with 3 H-prazosin (0.04 to 1.2 nmol/l, PerkinElmer, Waltham, Massachusetts); phentolamine (10 mol/l, Sigma #P7561) defined nonspecific binding. The ␤-AR binding used 50 g membrane protein/tube with 125 I-cyanopindolol (CYP) (0.04 to 1.0 nmol/l, NEN Life Sciences, PerkinElmer); L-propranolol (1 mol/l, Sigma #P8688) defined nonspecific binding (17) . The ␣1-AR subtype proteins were assayed with competition for 3 Hprazosin binding (0.5 nmol/l) by BMY-7378 (0.05 nmol/l to 500 mol/l, Sigma #B134), an ␣1D-selective antagonist (18) . All incubations were 60 min at 30°C. Binding data were analyzed by Prism 4.0b (GraphPad Software, Inc., San Diego, California). Coronary artery smooth muscle cell culture and immunoblots. Human coronary arteries were digested 20 min in Hanks buffer with collagenase Type II (1 mg/ml, Worthington, Lakewood, New Jersey) and elastase (0.5 mg/ml, Worthington), and intima and adventitia were removed mechanically. Rings of media (approximately 2 mm) were cut free hand and cultured. Other rings were minced and digested for 2 h in collagenase and elastase; enzymes were inhibited with serum; and smooth muscle cells (SMCs) grew out of the minces (19) . Clonetics normal human coronary artery SMCs were from Lonza (#CC2583, Walkersville, Maryland). All cells were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum for 8 to 48 h (rings) or 3 to 11 passages (cells). For experiments, cultures were incubated in Dulbecco's modified Eagle's medium without serum with 5 mg/ml bovine serum albumin (Sigma #A7030) for at least 12 h (rings) or 48 h (cells), pretreated without or with ␣1-antagonists (10 nmol/l BMY-7378; 1 mol/l prazosin, Sigma #P7791) for 90 min (rings) or 15 min (cells) and treated with ␣1-agonists (1-200 nmol/l L-NE, Sigma #N5785; 10 nmol/l A61603, Tocris #1052, Ellisville, Missouri), in the presence of the ␤-AR antagonist L-propranolol (1 mol/l). After 30 min (rings) or 15 min (cells), homogenates were made in radioimmunoprecipitation assay buffer with protease and phosphatase inhibitors. Ring homogenates were centrifuged at 12,000 rpm for 20 min at 4°C. The supernatant (rings) or total lysates (cells) were used (10 to 20 g protein/lane) for immunoblotting with antibodies from Cell Signaling for total-extracellular signal-regulated kinase (ERK) 1/2 (rabbit pAb #9102) and phospho-ERK1/2 (rabbit mAb Thr202/Tyr204 #4370) and antibodies for phospho-S19/20-myosin light chain 2 (MLC), including Sigma #M6068, Cell Signaling #3671, and abcam #ab2480. ACEI ϭ angiotensin-converting enzyme inhibitor; AF ϭ atrial fibrillation/flutter; Amio ϭ amiodarone; ARB ϭ angiotensin receptor blocker; AS ϭ aortic stenosis; BB ϭ ␤-blocker; CA ϭ cancer; CAD ϭ coronary artery disease; CCB ϭ calcium-channel blocker; CKD ϭ chronic kidney disease; CoHD ϭ congenital heart disease; COPD ϭ chronic obstructive pulmonary disease; CPVT ϭ catecholaminergic polymorphic ventricular tachycardia; D ϭ diuretic; DA ϭ dopamine; Db ϭ dobutamine; Dig ϭ digoxin; DM ϭ diabetes mellitus; EF ϭ ejection fraction; Epi ϭ epinephrine; HF ϭ heart failure; HTN ϭ hypertension; Hyd ϭ hydralazine; Ins ϭ insulin; Lev ϭ levothyroxine; MI ϭ myocardial infarction; Mil ϭ milrinone; Nip ϭ nitroprusside; Nit ϭ nitrates; PE ϭ phenylephrine; PSA ϭ polysubstance abuse; RHD ϭ rheumatic heart disease; Sar ϭ sarcoidosis; Sil ϭ sildenafil; VAD ϭ ventricular assist device; Vaso ϭ vasopressin; VT ϭ ventricular tachycardia; VTE ϭ venous thromboembolic disease. (20) . Specificity of the ␣1-subtype primers was confirmed with: 1) PCR with human ␣1-AR complementary deoxyribonucleic acid; 2) a dissociation step in all PCR reactions; and 3) sequencing of the PCR products. Amplification of genomic deoxyribonucleic acid was excluded by: 1) use of intron-spanning primers; 2) DNase treatment of RNA; and 3) end point PCR reactions with no-RT templates as negative controls. In human epicardial coronary arteries, the ␣1D was 85% of total ␣1-mRNA (Fig. 1A) . The ␣1B (11%) and the ␣1A (4%) were markedly less abundant than the ␣1D (p Ͻ 0.001 for each). In LV myocardium, by contrast, the ␣1D was only 21% of the total ␣1-mRNA, and the ␣1A (63%) was the most abundant (Fig. 1B) . The absolute level of ␣1D mRNA in coronary arteries was almost twice that in LV (p ϭ 0.01), whereas the absolute level of the ␣1A was 30-fold higher in LV than in coronary arteries. As a control, there was no difference between coronary arteries and myocardium in the qRT-PCR cycles-to-threshold for the reference genes, ␤-actin, and TATA-binding protein. Levels of ␣1-subtype mRNAs were the same in 4 right and 4 left anterior descending coronaries (data not shown). There were no differences in ␣1-subtype mRNA levels in coronaries collected at UCSF versus the CTDN hospitals, suggesting no important effects due to anesthetic and analgesic agents (data not shown).
Patient Characteristics
In summary, the ␣1D is 85% of total ␣1-AR subtype mRNA in human epicardial coronary arteries but is significantly less abundant in human LV myocardium. ␣1-AR subtype protein levels. To test ␣1-AR subtype protein levels we used radioligand binding with 3 Hprazosin. We could not use immunohistochemistry or immunoblot, because none of the 10 ␣1-AR antibodies that we tested is specific for ␣1-ARs (21).
We used pooled membranes from 11 patients for binding. Patient characteristics were similar in these 11 patients and the entire patient population (Table 1) , and the ␣1-subtype mRNA levels in the pooled samples were similar to the levels of the entire group (data not shown). Saturation binding identified 8.7 fmol/mg protein of total ␣1-ARs in coronary artery membranes, with a Kd 0.03 nmol/l, and specific binding 70% of total at the 3 H-prazosin Kd (Fig. 2) . The level of ␣1-AR binding in coronaries was roughly twice that in LV myocardium (20) .
To test whether the ␣1D subtype protein was also predominant in coronaries, as with mRNA, we did competition binding with the ␣1D-selective antagonist BMY-7378. The BMY-7378 competition yielded a 2-site binding curve (p ϭ 0.002 vs. 1-site model), with 75% high-affinity sites (Kd 13 pmol/l) and 25% low-affinity (2.6 mol/l) (Fig. 3A, Table 2 ). In ventricular myocardium, BMY competition gave a 1-site curve with low BMY-7378 affinity, indicating minimal or no ␣1D binding (Fig. 3B) . In summary, the ␣1D is 75% of total ␣1-AR subtype protein in human epicardial coronary arteries but is much less abundant in myocardium. The coronary levels of ␣1D mRNA and protein agree very well (Table 2) . ␣1-AR signaling in coronary SMCs. To test whether the ␣1D was functional in human coronary SMCs, we used immunoblot to quantify phosphorylation (activation) of ERK, which is a target for the ␣1D in rat aortic SMCs (22) and is involved in activation of MLC kinase in smooth muscle (23) . We used SMCs from Lonza, coronary media rings, and primary isolates from the coronary medial SMC layer (Fig. 4) . A qRT-PCR for ␣-smooth muscle actin and smooth muscle myosin heavy chain confirmed SMC identity, and ␣1D mRNA was the predominant ␣1-subtype, with less ␣1B and no ␣1A (data not shown). Low concentrations of NE (mean 27 nmol/l), in the presence of propranolol to block ␤-ARs, induced a 1.8-fold increase in phospho-ERK, and activation was abrogated to an equal extent by a low concentration of BMY-7378 (10 nmol/l), the ␣1D-selective antagonist, and prazosin, the nonselective ␣1-antagonist (Fig. 4) . The ␣1A-selective agonist, A61603 (10 to 100 nmol/l), did not activate ERK (data not shown). Phospho-MLC was barely detectable with 3 different antibodies and was not useful as a read-out (data not shown).
We conclude that the ␣1D is functional in human epicardial coronary SMCs, whereas there is no evidence for the ␣1A. ␤-AR mRNA and protein levels. We measured ␤-AR mRNAs and protein in the same coronary arteries, to compare with ␣1-ARs. By qRT-PCR (20) the ␤2 was the predominant ␤-subtype mRNA (99% of total ␤-AR mRNA) ( Table 2) . Total ␣1-AR mRNA was 37% of total ␤-AR mRNA (p Ͻ 0.0001) ( Table 2 ).
The ␤-AR proteins were quantified by saturation binding, because the available ␤-AR antibodies are not specific in our hands (12) . Saturation binding with 125 I-CYP, a nonselective ␤-AR antagonist, identified 25.2 fmol/mg protein of total ␤-ARs in coronary artery membranes, with a Kd 0.16 nmol/l and specific binding 41% of total at the 125 I-CYP Kd (Fig. 2B) . Given the preponderance of ␤2-mRNA in coronary tissue, ␤-AR competition binding was not done. Total ␣1-AR binding was 35% of total ␤-AR binding, in excellent agreement with the mRNA values ( Table 2) . In summary, the ␤2 was the predominant ␤-AR subtype in epicardial coronary arteries, and ␣1-AR mRNA and binding were only one-third of ␤-ARs. Impact of clinical variables on coronary ␣1-and ␤-AR mRNA levels. The qRT-PCR results were analyzed to determine whether clinical variables affected the expression of AR subtypes in human coronaries. Human noncoronary arterial and prostate ␣1-ARs are said to increase with age (9, 24) , and ␣1-mediated vasoconstriction is more prominent in CAD (1-4). However, we found that age, EF, ␤-agonist exposure, CAD (Fig. 5) , and sex (data not shown) had no effect on coronary artery ␣1-subtype mRNA levels. Interestingly, ␣1D and total ␣1-mRNA levels were 35% lower in coronary arteries of patients using ␤-blockers (p ϭ 0.04). This association persisted after adjusting for age, sex, CAD, and EF (p ϭ 0.03) (Fig. 5B) . Among ␤-blockers, ␣1D mRNA levels appeared similar among patients taking metoprolol (1 patient), nadolol (1 patient), or carvedilol (8 patients) (Fig. 5B) .
The levels of coronary ␤-AR mRNAs, which were almost entirely ␤2, did not vary with age, EF, ␤-blocker or ␤-agonist use, or sex (data not shown).
In summary, age, sex, CAD, EF, and ␤-agonists had no significant effect on ␣1-or ␤-subtype mRNA levels in coronary arteries. Beta-blocker use was associated with a significant decrease in ␣1D and total ␣1-mRNA levels.
Discussion
This study reports that the ␣1D subtype is the predominant ␣1-AR in human epicardial coronary arteries, comprising approximately 80% of total ␣1-AR mRNA and protein. These data also reveal that coronary ␣1-AR levels are only one-third of ␤-ARs. This is the most extensive characterization of ␣1-AR subtypes in coronary tissue in any species.
Our results disagree with those of a previous investigation that identified the ␣1A as the predominant ␣1-subtype in human coronary arteries (9) . In our study, the ␣1A in the coronaries was only 4% of total ␣1-mRNA in coronaries and was absent in isolated SMCs, and the combined ␣1A and ␣1B were only 25% of total ␣1-binding. The discrepancy might be explained by the prior study's small sample size (5 arteries from an unspecified number of patients), the use of post-mortem tissue, or a qualitative RNA assay (RNase protection) (9) .
Of particular importance is our finding that the ␣1-AR subtype profiles in the human coronary arteries and ventricular myocardium were quite different. Previous limited evidence suggests that ␣1A subtype mRNA is predominant in both coronary arteries and myocardium (9, 10) . In contrast, we found that the ␣1D was predominant in the coronary arteries but was much less abundant in the myocardium, where ␣1A mRNA was predominant. In the mouse heart, myocardium has the ␣1A and ␣1B subtypes (6), whereas the ␣1D subtype is functional in coronary arteries (7, 8) . Thus, rodents and humans might have similar ␣1-AR subtype expression in coronary arteries and myocardium (7, 8, 17, 20, (25) (26) (27) (Table 3) , contrary to prior claims (9) , and studies done in mouse models might therefore be applicable to human cardiac ␣1-AR biology. Technical aspects of this study warrant emphasis. We studied coronaries from a large number of patients of both sexes without and with CAD or heart failure and assessed the effects of these variables on ␣1-AR expression. We took extensive measures to validate our qRT-PCR approach. We quantified ␣1-subtype proteins by competition binding, because binding is for now the only accurate method to measure ␣1-AR proteins (21) .
␣1-AR mRNAs and Proteins in Human Epicardial Coronary Arteries
We also measured ␤-AR subtypes in the coronaries and found that ␣1-AR levels were only one-third of ␤-ARs.
However, these lower ␣1-AR levels do not negate the physiological significance of the ␣1D. The contractile response to NE in isolated human epicardial coronary arteries is constriction at low concentrations (nmol/l) and relaxation at high concentrations (mol/l) (28) . The ␣1D has the highest NE affinity of any subtype (29) , and thus constriction at low NE concentrations is consistent with an ␣1D-response. The larger population of coronary ␤-ARs could mediate relaxation with mol/l NE.
Indeed, our experiments in epicardial coronary SMCs revealed that the ␣1D mediated activation of ERK by low concentrations of NE (Fig. 4) . ERK is activated by the ␣1D in rat aortic SMCs (22) , and ERK phosphorylation facilitates activation of MLC kinase in smooth muscle, thus contributing to the adrenergic contractile response (23) . These findings suggest that the ␣1D is both abundant and functional in human epicardial coronary arteries.
We analyzed coronary ␣1-and ␤-AR subtype mRNA levels by age, CAD, EF, ␤-blockers, and ␤-agonists (Fig. 5 ) and sex (data not shown). The only association we found was a decrease in the ␣1D and total ␣1-ARs in patients treated with ␤-blockers, possibly implying that ␣1D expression in coronary vascular cells is increased by ␤-stimulation. In fact, in human monocytes, ␤2-stimulation induces ␣1D mRNA and protein (30) .
Coronary ␣1-subtype mRNA levels did not differ in patients with CAD versus without CAD. This was noteworthy, because ␣1-ARs cause pronounced vasoconstriction in atherosclerotic coronary arteries but have little effect in normal coronaries (1-4). Thus, increased ␣1D levels in coronary vascular SMCs might not explain augmented ␣1-vasoconstriction in CAD. Instead, a small population of endothelial cell ␣1-ARs mediating endothelium-dependent vasodilation (31) could be lost in CAD. Clinical implications. Important clinical implications derive from the predominance of the ␣1D subtype in human coronary arteries. Cell and animal models show that the cardiac myocyte ␣1A and ␣1B subtypes have significant adaptive and protective roles (6, (11) (12) (13) 16) . Clinical trials also suggest ␣1-mediated cardioprotection, because nonselective antagonism of all ␣1-subtypes was associated with a 2-fold excess of heart failure in the doxazosin arm of the ALLHAT (Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial), and a trend towards Cardiac ␣1-AR Subtypes in Human, Mouse, and Rat increased mortality in the prazosin arm of the V-HeFT (Vasodilator-Heart Failure Trial) (14, 15) . Despite the ALLHAT trial results, 13.4 million prescriptions were dispensed in 2002 for mostly nonselective ␣-blockers (32), primarily to treat symptoms from prostate hypertrophy. However, the ␣1D-selective antagonist, naftopidil, is effective in relieving prostate symptoms (33) . In light of our results, it seems possible that more selective antagonism of the ␣1D subtype might relax both coronary and prostate smooth muscle, without blocking beneficial signaling mediated by the myocardial ␣1A and ␣1B subtypes. Furthermore, the adaptive and protective roles of the myocardial ␣1A and ␣1B raise the intriguing possibility of activating one or both of these subtypes selectively to treat myocardial disease (16) . The low levels of the ␣1A and ␣1B in human coronary arteries would make ␣1A-or ␣1B-agonist-induced coronary vasoconstriction unlikely.
Conclusions
We present here the most extensive characterization of human coronary ARs to date. We show that the ␣1D is the predominant ␣1-AR subtype in human epicardial coronary arteries-not the ␣1A as reported previously (9)-and that the ␣1D is low in myocardium. The ␣1A and ␣1B are present in coronaries at very low levels, and total ␣1-AR levels are one-third the level of ␤-ARs, most of which are the ␤2 subtype. The tissue distribution of ␣1-subtypes in the human heart is similar to the rodent heart (Table 3) . These results are clinically relevant to the widespread use of ␣1-antagonists and to the potential development of ␣1A-and/or ␣1B-AR-selective agonists.
